MEN1 and neoplasm: To assess whether an antagonist of β-catenin signalling could suppress the expansion and excessive insulin production of Men1-deficient tumours, βMen1-KO mice and isolated tumour cells were treated with PKF115-584, which is a small molecule antagonist of the TCF/β-catenin complex29.